PHRM-01. PLASMA AND CEREBROSPINAL FLUID PHARMACOKINETICS OF THE DNA HYPOMETHYLATING AGENT, GUADECITABINE (SGI-110), FOLLOWING SUBCUTANEOUS ADMINISTRATION IN A NON-HUMAN PRIMATE MODEL
Guadecitabine, a potent hypomethylating agent currently being studied in clinical trials, is a dinucleotide that is resistant to degradation by cytidine deaminase resulting in an extended release of the active metabolite decitabine following subcutaneous ...
22 Jun 2018 ... Cynthia M Lester McCully,1 Arman Odabs,1 Rafael Cruz,1,2 Cody Peer,1 William D Figg,1 John W Glod,1 and Katherine E Warren1 ...